TABLE 1.
Baseline clinicopathologic characteristics before AA treatment
| Variables | Whole cohort (N = 132) |
|---|---|
| Age (years) | 71 (36–85) |
| BMI (kg/m2) | 23.88 (18.51–30.86) |
| ECOG score | |
| 0 or 1 | 86 (65.15%) |
| 2 | 46 (34.85%) |
| ISUP grading group | |
| 1 | 12 (9.09%) |
| 2 | 22 (16.68%) |
| 3 | 34 (25.75%) |
| 4 | 45 (34.09%) |
| 5 | 19 (14.39%) |
| Clinical T stage | |
| 2 | 21 (15.91%) |
| 3 | 55 (41.67%) |
| 4 | 56 (42.42%) |
| ADT duration before AA | |
| <12 months | 67 (50.76%) |
| ≥12 months | 65 (49.24%) |
| Metastatic sites | |
| Bone only | 64 (48.48%) |
| Viscera | 68 (51.52%) |
| PSA at diagnosis (ng/ml) | 13.10 (4.10–96.00) |
| PSA at abiraterone start (ng/ml) | 10.37 (1.11–91.76) |
| SMI (cm2/m2) | 49.71 (32.15–76.55) |
| VFA (cm2) | 126.65 (55.85–216.53) |
| SFA (cm2) | 134.52 (76.55–201.32) |
| TFA (cm2) | 255.83 (150.21–385.54) |
| rVFA | 0.48 (0.33–0.58) |
| PPFA (cm2) | 12.65 (5.52–21.47) |
| PPFA/PA | 0.94 (0.42–2.50) |
| PPFT (mm) | 9.25 (1.23–16.59) |
| PPFT/SFT | 0.32 (0.05–0.72) |
Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group performance status score; SFA, subcutaneous fat area; ISUP, International Society of Urological Pathology; PPFA/PA, periprostatic fat area/prostate area; PPFA, periprostatic fat area; PPFT/SFT, periprostatic fat thickness/subcutaneous fat thickness; PPFT, periprostatic fat thickness; PSA, prostate‐specific antigen; rVFA, relative visceral fat area; SMI, skeletal muscle index; TFA, total fat area; VFA, visceral fat area.